Latest Lead News

Red Mountain Mining has raised $400,000 through convertible notes to fund drilling at its Kiabye Gold Project in Western Australia and further exploration at the Armidale Antimony-Gold Project in New South Wales.

Equinox Resources has successfully raised A$3 million through a strategic placement to fund key milestones across its titanium, antimony, and iron ore assets. The capital injection aims to drive resource estimation, drilling, and legal progress in multiple jurisdictions.

Codrus Minerals has obtained a significant drilling permit for its Bull Run Gold Project in Oregon, reviving exploration at a historically productive site with promising past results and strong government support.

Helia Group’s 1Q25 APRA lodgement reveals robust growth in gross written premiums and statutory net profit, while the company voices concerns over proposed government changes to the Home Guarantee Scheme that could reshape its market dynamics.

Redivium Limited has launched its Trading Division and secured key agreements as it pushes forward with European battery recycling projects, though funding challenges remain.

Lloyds Banking Group reported a resilient start to 2025 with statutory profit after tax of £1.1 billion, underpinned by solid lending and deposit growth. The bank reaffirmed its 2025 guidance, maintaining confidence despite economic uncertainties.

Judo Capital Holdings updates its FY25 outlook, reporting stable margins and operational progress but slowing loan growth due to market uncertainties and higher provisioning.

Oncosil Medical Ltd has announced a significant 400-for-1 security consolidation affecting shares, options, and performance rights, with shareholder approval scheduled for late May 2025.

AdAlta Limited has announced a renounceable rights issue to raise up to $1.3 million, aiming to accelerate its ‘East to West’ cellular immunotherapy strategy and explore new strategic options.

Taruga Minerals has exercised its option to acquire 100% of the Thowagee Project in Western Australia's northern Gascoyne province, revealing promising high-grade assays of lead, silver, zinc, copper, and gold. This acquisition significantly expands Taruga's contiguous landholding, positioning the company for further exploration success.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

Dimerix has inked an exclusive US licensing agreement with Amicus Therapeutics for DMX-200, a promising Phase 3 treatment for FSGS, unlocking $30 million upfront and up to $560 million in milestones.